Nitroreductase‐Mediated Release of Inhibitors of Lysine‐Specific Demethylase 1 (LSD1) from Prodrugs in Transfected Acute Myeloid Leukaemia Cells

Lysine‐specific demethylase 1 (LSD1) has evolved as a promising therapeutic target for cancer treatment, especially in acute myeloid leukaemia (AML). To approach the challenge of site‐specific LSD1 inhibition, we developed an enzyme‐prodrug system with the bacterial nitroreductase NfsB (NTR) that wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Herrlinger, Eva‐Maria, Hau, Mirjam, Redhaber, Desiree Melanie, Greve, Gabriele, Willmann, Dominica, Steimle, Simon, Müller, Michael, Lübbert, Michael, Miething, Christoph Cornelius, Schüle, Roland, Jung, Manfred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Full Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497180/
https://www.ncbi.nlm.nih.gov/pubmed/32227662
http://dx.doi.org/10.1002/cbic.202000138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497180/
https://www.ncbi.nlm.nih.gov/pubmed/32227662
http://dx.doi.org/10.1002/cbic.202000138

Ejemplares similares